(Stockholm, Sweden, 13 January 2025) Inhalation Sciences (ISAB) announces its plans to launch the company’s XposeALI® in vitro exposure module, now with microperfusion. The development work was undertaken in 2024 with the final testing and validation being performed in a study co-financed with one of the company’s longstanding global pharmaceutical customers. …
